Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.59 |
| ▸ | HCRTR1 | O43613 | 18/20 | 0.51 |
| ▸ | HCRTR2 | O43614 | 18/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19385343 | 0.87 | USP30 (0.66) | USP30HCRTR1HCRTR2 | |
| SCHEMBL19385344 | 0.87 | USP30 (0.66) | USP30HCRTR1HCRTR2 | |
| SCHEMBL9605087 | 0.83 | USP30 (0.59) | USP30HCRTR1HCRTR2 | |
| SCHEMBL2777787 | 0.82 | HCRTR1 (0.46) | HCRTR1HCRTR2 | |
| SCHEMBL9605111 | 0.82 | USP30 (0.57) | USP30HCRTR1HCRTR2 | |
| SCHEMBL9605182 | 0.82 | USP30 (0.57) | USP30HCRTR1HCRTR2 | |
| SCHEMBL9605169 | 0.81 | USP30 (0.51) | USP30HCRTR1HCRTR2 | |
| SCHEMBL28590668 | 0.81 | USP30 (0.58) | USP30HCRTR1HCRTR2 | |
| SCHEMBL28590669 | 0.81 | USP30 (0.58) | USP30HCRTR1HCRTR2 | |
| SCHEMBL12332122 | 0.80 | USP30 (0.55) | USP30HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8623899-B2 | Bis-benzimidazole derivatives as hepatitis C virus inhibitors | Janssen Research & Development Ireland (IE) | 2014-01-07 | — | — | US | disclosed |
| US-8623899-B2 | Bis-benzimidazole derivatives as hepatitis C virus inhibitors | Janssen Research & Development Ireland (IE) | 2014-01-07 | — | — | US | disclosed |
| US-20120135953-A1 | Bis-Benzimidazole Derivatives As Hepatitis C Virus Inhibitors | TIBOTEC PHARMACEUTICALS (IE) | 2012-05-31 | — | — | US | disclosed |
| US-20120135953-A1 | Bis-Benzimidazole Derivatives As Hepatitis C Virus Inhibitors | TIBOTEC PHARMACEUTICALS (IE) | 2012-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120135953-A1 | Bis-Benzimidazole Derivatives As Hepatitis C Virus Inhibitors | HAVCR2, ZC3HAV1, CCNI | USP30 2065/4885HCRTR1 3448/4885HCRTR2 4538/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.